SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Bio Green Med Solution, Inc.
Date: April 28, 2025 · CIK: 0001130166 · Accession: 0001641172-25-006378

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286754

Date
April 25, 2025
Author
Chief
Form
CORRESP
Company
Bio Green Med Solution, Inc.

Letter

Cyclacel Pharmaceuticals, Inc.

Level 10, Tower 11, Avenue 5, The Horizon

Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

April 28, 2025

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

via EDGAR

RE: Cyclacel Pharmaceuticals, Inc. (CIK0001130166)

Registration Statement on Form S-1

Filed: April 25, 2025

Securities Act File No.: 333-286754

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the "Registrant") hereby respectfully requests acceleration of its Registration Statement on Form S-1 (File No. 333-286754), filed on April 25, 2025, so that it will become effective at 4:00 p.m. (Eastern time) on April 29, 2025, or as soon as practicable thereafter.

If you have any questions, or require any additional information, please do not hesitate to email Debbie Klis, the Registrant's outside counsel, at debbie.klis@rimonlaw.com or phone on 202-935-3390.

Very
truly yours,
Cyclacel
Pharmaceuticals, Inc.

Show Raw Text
CORRESP
 1
 filename1.htm

 Cyclacel
Pharmaceuticals, Inc.

 Level
10, Tower 11, Avenue 5, The Horizon

 Bangsar
South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

 April
28, 2025

 Securities
and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E.

 Washington,
DC 20549

 via
EDGAR

 RE:
 Cyclacel
 Pharmaceuticals, Inc. (CIK0001130166)

 Registration
Statement on Form S-1

 Filed:
April 25, 2025

 Securities
Act File No.: 333-286754

 Request
for Acceleration of Effectiveness

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the "Registrant") hereby respectfully
requests acceleration of its Registration Statement on Form S-1 (File No. 333-286754), filed on April 25, 2025, so that it will become
effective at 4:00 p.m. (Eastern time) on April 29, 2025, or as soon as practicable thereafter.

 If
you have any questions, or require any additional information, please do not hesitate to email Debbie Klis, the Registrant's outside
counsel, at debbie.klis@rimonlaw.com or phone on 202-935-3390.

 Very
 truly yours,

 Cyclacel
 Pharmaceuticals, Inc.

 By:
 /s/
 Datuk Dr. Doris Wong

 Datuk
 Dr. Doris Wong

 Chief
 Executive Officer